Slow Inbrija launch forces Acorda to slash $800M sales hopes by Kyle Blankenship Thursday, February 13, 2020 Acorda had high hopes for Parkinson's med Inbrija, aiming for$800 million in peak sales, but a lackluster year has the company rethinking that goal.
Acorda's sales team switches gears to promote Inbrija by Carly Helfand Tuesday, January 15, 2019 Acorda has moved its entire salesforce over from Ampyra to new launch Inbrija. But it’s not relying solely on that team to get the ball rolling.
Acorda pulls off delayed Parkinson’s approval for Inbrija by Carly Helfand Wednesday, December 26, 2018 Acorda has pulled off a crucial approval for Parkinson’s drug Inbrija, but that doesn’t mean the company is out of the woods.
Acorda's much-needed Inbrija hits a snag at the FDA by Eric Sagonowsky Thursday, September 13, 2018 After losing a last-ditch court battle against Ampyra generics, Acorda now faces an FDA delay on its new Parkinson's drug Inbrija.
Acorda desperately needs Inbrija nod after appeals loss by Eric Sagonowsky Tuesday, September 11, 2018 Acorda faces the prospect of generic competition on its primary revenue source, Ampyra, after an appeals court's decision.
CEO: Win or lose on Ampyra, Acorda's reps are safe with Inbrija by Carly Helfand Wednesday, June 6, 2018 Even if Acorda loses its upcoming appeal on Ampyra's patents, its sales force won’t have to worry, CEO Ron Cohen says.
